SLC12A5 and epilepsy: Restoring Cl- homeostasis could reduce the seizure severity by the NKCC1 inhibitor bumetanide or optogenetic removal of Cl- (Moore et al., 2017), suggesting that NKCC1 and KCC2 are the key regulators of GABAergic inhibition which are potential targets for the treatment of epilepsy.